The winter epidemic situation in the United States seems to be very serious.
On October 26, according to CCTV News, US President Biden received a booster vaccine against the Omickron mutant strain of the new coronavirus on the 25th, and warned that the epidemic may worsen after the United States enters winter. Hundreds of people in the United States still lose their lives due to infection with the new coronavirus every day, and this number may rise this winter. However, the effectiveness of the latest new crown vaccine bivalent enhancement injections launched by American vaccine giants Moderna and Pfizer has been suddenly questioned.
At the same time, a major domestic news completely triggered the domestic vaccine giant. On October 25, " Shanghai released " officially announced that Shanghai launched the inhaled recombinant coronavirus vaccine (type 5 adenovirus vector) to strengthen immunization appointment registration on the 25th, and started strengthening immunization from the same day. Affected by this, the stock price of the domestic vaccine giant CanSino Biologics completely exploded. As of the close of the market on the 26th, CanSino Biologics A shares and H shares rose by 20% in a single day. The latest stock price of CanSino Biologics A shares has exceeded 45% compared with the lowest point of the cumulative increase of .
In addition, the latest research published in two authoritative journals has also attracted global attention. Among them, a large study published by British scientists showed that patients with mild COVID-19 are 2.7 times more likely to develop thrombosis than those who have not been infected with the new coronavirus; patients with severe thrombosis are 28 times more likely to develop thrombosis than ordinary people; in addition, an article published in "Nature Human Behaviour", a sub-publication of the world's most authoritative journal " Nature ", shows that the new crown epidemic has caused the population life expectancy in most European and American countries to decrease.
Biden suddenly warned
At present, the United States is facing harassment from a variety of new crown mutant strains, and the risk of the outbreak of the epidemic again in the winter of 2022 is relatively high.
On October 26, CCTV News reported that US President Biden received a booster vaccine against the Omickron mutant strain of the new coronavirus on the 25th, and warned that the epidemic may worsen after the United States enters winter. At the same time, Biden also warned that hundreds of people in the United States still lose their lives due to the coronavirus infection every day, a number that may rise this winter.
However, the effectiveness of the latest new crown vaccine bivalent enhancement injection launched by American vaccine giants Moderna and Pfizer has been suddenly questioned.
According to the latest research from Columbia University and University of Michigan , the latest bivalent enhancement injection of the new crown vaccine launched by Moderna and Pfizer will not bring short-term immune advantages. The antibody level after 3 to 5 weeks of the new injectable enhancer needle is similar to the original antibody level after inoculation.
It is reported that researchers from Columbia University and the University of Michigan compared the levels of antibody in 21 people who were injected with Moderna or Pfizer bivalent booster injections with 19 people who were injected with four shots of the original vaccine. The results of the
study showed that after 3 to 5 weeks of injection, people who received the bivalent vaccine had similar numbers of neutralizing antibodies to those who received the fourth normal booster injection.
It should be pointed out that the latest bivalent vaccine is mainly to deal with the new coronavirus Omickron BA.4 and BA.5 variants.
Virologist David Ho of Columbia University pointed out that so far, research has not found that bivalent vaccines have an advantage over old vaccines, and perhaps the obvious differences between the enhanced shots will appear over a longer period of time. The research results of
indirectly negate the on-site trials officially disclosed by Pfizer and BioNTech. Previously, Pfizer officially announced that "positive early data" showed that the bivalent enhancement injection of the new crown vaccine "is expected to provide better protection." But so far, Pfizer has not released details.
is worth mentioning that so far, the promotion of bivalent vaccines in the United States has not been smooth. According to data from the U.S. Centers for Disease Control and Prevention, only about 20 million Americans have received the latest version of the bivalent enhancement injection.
According to " US News and World Report ", the United States is currently dealing with 8 Omickron mutant strains at the same time. This situation puts the United States at the risk of a new wave of epidemic this winter.
Domestic vaccine giants soared 45%
At the same time, a major domestic news suddenly triggered the domestic vaccine giants.
On October 25, "Shanghai Release" officially announced that Shanghai will launch the registration of immune reservations for inhaled recombinant coronavirus vaccine (type 5 adenovirus vector) on the 25th, and will initiate the registration of immune strengthening from the same day.
At the same time, "Shanghai Release" stated that for people aged 18 years old and above who have been vaccinated with the new crown vaccine (type 5 adenovirus vector) for 6 months, they can choose to use the inhaled recombinant new crown virus vaccine (type 5 adenovirus vector) for one dose to strengthen immunization. Free vaccination is implemented for strengthening immunization.
was stimulated by this news. The stock price of domestic vaccine giant CanSino Biologics completely broke out. On October 25, rose violently at the end of the trading session, and H shares rose nearly 9% in a single day; on the 26th, the prices of A shares and H shares rose strongly again, and H shares rose by more than 22% during the session. As of the closing of the day, CanSino Biologics' A shares and H shares both rose by about 20%. Among them, CanSino's latest share price closed at 160.76 yuan, an accumulated increase of more than 45% compared with the lowest point. The main reason why the market funds are pursuing CanSino Biologics is that its inhaled new crown vaccine has completed the first and second phase clinical trial data in 2021. At the same time, Zhu Tao, chief scientific officer of CanSino Biologics, said that CanSino Biologics' world's first inhaled new crown vaccine, used the same vaccine as intramuscular injection. The formulation of its preparation has not changed and only uses different dosing methods.
In early September this year, CanSino Biologics officially announced that the recombinant novel coronavirus vaccine (inhalation new coronavirus vaccine) developed by the company was proposed by the National Health Commission, and the National Medical Products Administration organized the demonstration and agreed to be included in emergency use as a strengthening injection.
In addition, data disclosed by CanSino shows that the latest research results show that the use of this vaccine for sequential strengthening, the neutralizing antibody level against the Omickron variant strain is 14 times that of the homologous enhancement of inactivated vaccine , and the sequential strengthening of recombinant protein vaccine , and the protective power can be maintained at least 6 months.
It is reported that the recombinant new coronavirus vaccine for inhalation (type 5 adenovirus vector) mainly includes two parts: atomization and inhalation. The vaccine solution is atomized into fine particles through the atomization device and injected into the atomized cup. The recipient then completes "vaccination" through inhalation. The required dose is only 1/5 of the injectable adenovirus vector, which can form mucosal immunity, which is expected to reduce costs and improve the efficiency of vaccine use.
Zheshang Securities stated in the research report that the recombinant novel coronavirus vaccine for inhalation by CanSino Biologics was included in emergency use as a booster shot, and it is optimistic about the growth potential of the company's products approved.
2 major discoveries
As the global medical community deepens research on new crown patients, more authoritative discoveries have been gradually disclosed.
On October 24, local time, a large study published by British scientists showed that the risk of thrombosis in new coronavirus patients is higher than that in ordinary people, and the possibility of severe patients is significantly increased.
The study was published in the sub-publication "Hheart" of the British Medical Journal . The conclusions showed that patients with mild COVID-19 were 2.7 times more likely to develop thrombosis than those who did not have the new coronavirus. Once a blood clot appears, they are 10 times more likely to die than ordinary people.
At the same time, the study concluded that patients hospitalized for COVID-19 infection are 28 times more likely to develop thrombosis than ordinary people, 22 times more likely to develop heart failure is 17 times more likely to develop stroke. Overall, they are more than 100 times more likely to die than ordinary people.
The study tracked a total of 18,000 patients who had contracted the coronavirus in the first year of the coronavirus pandemic and compared their health status with nearly 34,000 people who did not have the virus.
It should be noted that most of the cases tracked by the study were conducted before the UK's large-scale promotion of vaccination.
scientists said that their research findings and results highlight that long-term monitoring of cardiovascular disease is very important even for patients with mild COVID-19. In countries with limited vaccination opportunities, this risk may be higher.
Regarding the link between the new crown and thrombosis, a study published by the American Heart Association in September this year also showed that even after a year of infection with the new crown, the risk of thrombosis among infected people is still higher than that of healthy people.
Another study on COVID-19 and population life expectancy has also attracted global attention. Recently, an article published in Nature Human Behaviour, the sub-publication of the world's most authoritative journal, shows that the new crown epidemic has caused a decline in the life expectancy (LE) of most countries in Europe and the United States.
This study was jointly participated by demographers from the Leverhume Center for Population Science at Oxford University and the Max Planck Institute in Germany. The report examines the changes in life expectancy of population in 29 countries (including Europe, the United States and Chile) over the two years from 2019 to 2021.
From the 29 countries analyzed, the population life expectancy of 12 countries fell sharply in 2021. Among them, the life expectancy of Bulgaria has the largest decline, a total of 3 years and 7 months in the past two years; followed by Poland , which is 2 years and 9 months; the United States on the other side of Atlantic ranked third, with a total of 2 years and 4 months.
In addition, on October 25, Reference News Network quoted the French Le Monde website that the COVID-19 pandemic caused an unprecedented decline in population life expectancy in Europe since World War II , which is more obvious in Eastern Europe and the United States.
Editor: Tactical Heng
Proofreading: Liao Shengchao
Illegal and Bad Information Reporting Tel: 0755-83514034
Email: [email protected]
